Dexcom (NASDAQ: DXCM) net income
Dexcom reported a net profit of $836.3m for fiscal 2025, 45.1% more than in fiscal 2024 ($576.2m). Its net margin was 17.9%. Earnings per share were $2.14.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $836.3m | +45.1% | 17.9% | $2.14 |
| 2024 | $576.2m | +6.4% | 14.3% | $1.46 |
| 2023 | $541.5m | +58.7% | 14.9% | $1.40 |
| 2022 | $341.2m | +57.3% | 11.7% | $0.88 |
| 2021 | $216.9m | −60.5% | 8.9% | $1.60 |
| 2020 | $549.7m | +443.7% | 28.5% | $5.23 |
| 2019 | $101.1m | — | 6.8% | $1.11 |
| 2018 | −$127.1m | — | −12.3% | −$1.44 |
| 2017 | −$50.2m | — | −7.0% | −$0.58 |
| 2016 | −$65.6m | — | −11.4% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the net income of Dexcom
- How much did Dexcom earn in fiscal 2025?
- Dexcom reported a net profit of $836.3m for fiscal 2025. In fiscal 2024 it reported a net profit of $576.2m.
- What are the earnings per share of Dexcom?
- They were $2.14 in fiscal 2025, compared with $1.46 in fiscal 2024.
- What is the net margin of Dexcom?
- In fiscal 2025 its net profit was 17.9% of its revenue.
- What was the most profitable year for Dexcom?
- Of its last 10 fiscal years, fiscal 2025, with $836.3m.
- Where do the figures for Dexcom come from?
- From the annual report (Form 10-K) that Dexcom files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Dexcom files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Dexcom: the Dexcom page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.